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ABSTRACT

Glioblastoma multiforme (GBM), a grade IV glioma, is the most common type of primary brain
tumor, affecting about 3 out of 100,000 persons per year in the United States. GBM accounts for
about 80% of primary malignant brain tumors, and is also the most aggressive of malignant brain
tumors. With exhaustive treatment, survival only averages between 12 and 15 months, with a 2year survival rate less than 25%. New therapeutic strategies are necessary to improve the
outcomes of this disease. Chemotherapy with temozolomide (TMZ), a DNA alkylating agent, is
used as a first-line of treatment for GBM. However, GBM tumors develop resistance to TMZ over
time due to increased expression of O6-methylguanine-DNA methyltransferase (MGMT), a gene
responsible for DNA repair.
We previously developed cationic, amphiphilic copolymer poly(lactide-co-glycolide)-gpolyethyleneimine (PgP) and demonstrated its utility for nucleic acid delivery. Here, we examine
the ability of PgP polyplexes to overcome TMZ resistance and improve therapeutic efficacy
through combination drug and gene therapy for GBM treatment. In this study, we evaluated the
ability of PgP to deliver siRNA targeting to MGMT (siMGMT), a gene responsible for drug
resistance in GBM. Our results demonstrated that PgP effectively forms stable complexes with
siRNA and protects siRNAs from heparin competition assay, serum- and ribonuclease-mediated
degradation, confirming the potential of the polyplex for in vivo delivery. Results from MTT assays
showed that PgP/siRNA polyplexes exhibited minimal cytotoxicity compared to untreated cells
when incubated with T98G human GBM cells. We also demonstrated that PgP/siMGMT
polyplexes mediate knockdown of MGMT protein as well as a significant ~56% and ~68%
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knockdown of MGMT mRNA in T98G GBM cells compared to cells treated with PgP complexed
with non-targeting siRNA (siNT) at a 60:1 and 80:1 nitrogen:phosphate (N:P) ratio, respectively.
Further, co-incubation of PgP/siMGMT polyplexes with TMZ enhanced therapeutic efficacy in
T98G GBM cells compared to treatment with the polyplex or TMZ alone. After generation of
athymic mouse GBM model, PgP/siMGMT polyplexes were locally injected into the tumor.
Relative to untreated injury only, PgP/siMGMT polyplexes significantly reduced MGMT mRNA
and protein expression at 3 days post-injection. These studies demonstrate that PgP is an
efficient non-viral delivery carrier for therapeutic siMGMT to the tumor cells and may be a
promising platform for the combinatorial siRNA/drug therapy for GBM treatment. In the future,
we will study the therapeutic efficacy of the combination of PgP/siMGMT and TMZ in athymic
mouse GBM model.
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CHAPTER 1
INTRODUCTION & BACKGROUND
Each year over 25,000 new malignant brain tumors are to be diagnosed in the United
States. With 700,000 Americans currently living with malignant brain tumors, over 170,000 are
expected to die this year due to the cancer. With a median age of diagnosis of 64, brain tumors
may seem to be a factor of aging, but they are also the most common cancer occurring in
children under the age of 15. Brain tumors are the leading cause of cancer-related death in
children between the ages of 0 and 14, and the third most common cancer-related death in
young adults between the ages of 15 and 39.1
There are more than 100 distinct types of primary brain and central nervous system
tumors, the most common being meningiomas and gliomas. Meningiomas make up 36.6% of all
primary brain tumors, but gliomas make up 74.6% of all malignant brain tumors. Gliomas arise
from the glial, or supportive cells in the brain,
such as astrocytes or oligodendrocytes.2
Glioblastoma multiforme (GBM) is a high-grade
glioma that arises from astrocytes, making it a
type of astrocytoma. The World Health
Organization (WHO) assigns four grades to
astrocytomas, where glioblastomas
make up grade IV.3,4 GBM makes up

Figure 1. The CBTRUS (Central Brain Tumor Registry of the
United States) reports distribution of histological subtypes of
primary brain and CNS gliomas, where GBM makes up 54.4%
(N= 92,504). 1

about 55% of all gliomas, affects about 3
in 100,000 people, and an estimated 12,400 new cases are predicted in 2017. Glioblastomas are
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not only the most common malignant primary brain tumor, but also the most aggressive.5
Without treatment, the survival rate for GBM is 2-3 months, and with aggressive treatment,
survival averages between 12 and 15 months.6,2 The five year survival rate is less than 5%, due in
part to inefficacy of treatment modalities.4 GBM is about 2 times more common in whites than
blacks, and 1.5 times more common in men than in women.1 Clinically, patients present with
headaches, neurological symptoms such as confusion, memory loss, seizures or personality
change.
The current standard of care for treating GBM includes maximal surgical resection of the
tumor, radiation therapy and chemotherapy via temozolomide (TMZ).7 Carmustine (BCNU,
Gliadel ™) wafers have been used as adjuvant local therapy in combination with systemic TMZ,
but use has been limited due to observed toxicities and ambiguity of overall survival benefit.8,9
Additionally, bevacizumab, a monoclonal antibody for the inhibition of vascular endothelial
growth factor (VEGF), has been used since its approval as a treatment for recurrent
glioblastomas.10 However, the 2-year survival rate after treatment remains at about only 25%.11
GBM remains an essentially incurable disease, with recurrences taking place in most cases. High
grade gliomas tend to be not only located in undesirable locations in the cerebral hemispheres,
but they also have high rates of invasion into surrounding brain tissue. These factors allow for
persistent tumor growth, and low chance of patient remission. Most adult gliomas are classified
as diffuse gliomas, where the tumor cells diffuse into normal preexisting brain tissue. Most low
grade diffuse gliomas will eventually develop into grade III or grade IV gliomas.3,11
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1.1 Etiology
Primary brain tumors are histologically highly heterogeneous, where even between
studies classifications and groupings of tumors often differ. The name glioblastoma
“multiforme” is indicative of its heterogeneity. GBM is multiforme grossly, where some regions
are necrotic, where others are hemorrhagic. On the microscopic level, regions can be found of
pleomorphic nuclei, pseudopalisading necrosis, as well as microvasculature proliferating. GMB is
genetically multiforme where various mutations, increased expression, or deletions cause
tumorgenicity.5
Histologically, glioblastoma can be diagnosed or confirmed in part due to the patterns of
necrotic areas that occur within the tumor. The most common or symbolic of which is the
pseudopalisading necrosis, where many small irregularly shaped necrotic foci are within densepacked, radially oriented glioma cells. The necrotic regions are highly hypoxic, and have shown
to express high amounts of hypoxia-inducible factor 1a (HIF-1a), and produce increased quantity
vascular endothelial growth factor (VEGF), which attempt to allow for inflammation and
angiogenesis in the necrotic regions.12 The next most common necrotic pattern is described as
having large regions of necrosis, with necrotic tumor cells and vessels. This type contains an
intact layer of glioma cells surrounding a vessel, likely having becoming ischemic with lack of
blood supply. This second type of large necrotic areas is found in almost all primary GBM,
compared with only half of secondary GBM.13
Etiologically, various risk factors have been linked to the onset of GBM, including
smoking unfiltered cigarettes, petroleum refining work, and synthetic rubber manufacturing.14
Other environmental risk factors include exposure to ionizing radiation, such as therapeutic,

3

exposure to vinyl chloride and to pesticides. A study done by Burch et al. showed that adults
with brain tumors reported more use of hair dye and hair spray compared to control.15 The
Central Brain Tumor Registry of the United States (CBTRUS) created the map shown in Figure 2
using data from 2006 to 2010, displaying distribution of malignant primary brain tumors
throughout the United States. Geography and environmental factors pertaining to location
display possible correlation of malignancies with the northern regions of the United States. 1

Figure 2. The CBTRUS (Central Brain Tumor Registry of the United States) reports distribution of average
incidence rates of malignant primary brain and CNS tumors across the US. 1

Zahm et al. summarized 17 studies done on the relationship between pesticide exposure
and pediatric brain tumors. Pesticide exposure was considered a mother using household
pesticides or insecticides, a father working in an agricultural setting, and child contact with pets.
Nine out of 17 studies showed statistically significance between exposure and brain tumor
development, while 5 studies showed nonsignificant correlation, and 3 studies showed no
association.16 Factors including exposure to electromagnetic fields (EMF), formaldehyde,
diagnostic radiation, and mobile phones have not be proven to be linked with the onset of
GBM.2 Hereditary syndromes, such as tuberous sclerosis and neurofibromatosis, family history,
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and allergies have also been studied as risk factors. 14 Although many factors have been
extensively studied, data is inconclusive in providing definitive measures for the prevention or
early diagnosis of GBM.
1.2 Pathogenesis
Glioma development occurs due to sequential acquisition of genetic alterations, causing
a transformation from benign to malignant tissue.17 Glioblastoma occurs in four clinical
subtypes, but most commonly in the form of classical, or primary GBM, and proneural, or
secondary GBM18 . Classical GBM arises de novo, and occurs in about 95% of cases, only taking
about 3-6 months to develop. Proneural, or secondary GBM arises as a recurrence from a
previous anaplastic or low-grade astrocytoma, usually taking 10-15 years to develop.13,2 Classical
GBM can be classified by increased expression of mutated epidermal-growth factor receptor
(EGFR), whereas secondary GBM has increased expression of platelet-derived growth factor
(PDGF-A) receptor. Various genetic alterations have been identified to lead to malignant
transformation and several will be described following.
Classical GBM presents not only with EGFR amplification, but almost always with an
amplification of chromosome 7 and a loss of chromosome 10. EGFR amplification is found in the
majority of classical cases.18 It can be found in a mutated form, with a truncation due to deletion
of exons 2-7. The mutated EGFR causes activation of the Ras-Sch-Grb2 pathway, allowing for
proliferation and suppression of apoptosis, and enhanced tumorgenicity. Commonly, primary
GBM presents with a phosphate and tensin homologue (PTEN) mutation and/or a p16INK4a
deletion as well as EGFR amplification.13,4 The p16 tumor suppressor (encoded by CDKN2A)
reduces the phosphorylation capacity of CDK4 and CDK6 cyclin-dependent kinases, therefore
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allowing the G1 to S-phase transition in the cell cycle. Most glioblastomas with EGFR
amplification show the p16 deletion as well.13 The phosphate and tensin homologue (PTEN)
mutation seen in 20% of glioblastomas causes downstream activation of the P13K/Akt/mTOR
pathway, and therefore increases cell survival and proliferation.19,20
Proneural GBM often presents with increased expression of platelet-derived growth
factor receptor (PDGFRA, PDGFR-α).13 Platelet-derived growth factor encourages development
and growth of connective tissues and glia. Two cell surface receptors (PDGFR-α and PDGFR-β)
belong to the tyrosine kinase family, and PDGFR-α has been found to be involved in tumor
proliferation. It has been found in low and high grade astrocytomas, and therefore is thought to
be part of the proliferation and development at all stages. PDGFR-α amplification is only found
in 16% of glioblastoma, but in most cases of secondary GBM.13 Proneural GBM tumors are not
only classified by increase PDGF-α, but also tumor suppressor (TP53) and retinoblastoma (RB)
gene mutations.4 TP53 is a transcription factor that activates genes and appears to act a stressinduced switch that can turn on arrested cell cycle in the G1 phase, or cause apoptosis. The TP53
mutation occurs in over 65% of secondary glioblastomas, but in less than 10% of primary GBM.
The accumulation of the TP53 protein is more frequently observed than the actual gene
mutation, and seen to be increasing in recurrent astrocytomas over time.13 TP53 induces the
transcription of the MDM2 gene (mouse double minute 2), and then MDM2 complexes with
TP53, as a negative feedback mechanism to stop its transcriptional activity. Upregulation of
MDM2 and the TP53-MDM2 complex formation can overcome the G1 checkpoint, and
contribute to the alternative pathways for the cell to evade the TP53 regulated control of cell
growth.13 Previous research with adenovirus-delivered TP53 showed functional restoration of
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the TP53 gene, leading to apoptosis in six glioma cell lines. Cellular proliferation was found to be
inhibited in both in vitro and in vivo models, which resulted in prolonged survival in preclinical
models.21 More recently, interferon-B (IFN-B) has been found to sensitize T98G (GBM) cells to
TMZ, thought to be a function of also being found to induce p53 overexpression.22 The
progression from low grade to high grade glioma is also associated with the blocked expression
of the retinoblastoma (RB) gene, which serves to halt the cell cycle, therefore causing
uncontrolled growth.20
A third, hybrid subtype of GBM called mesenchymal GBM exists, most commonly is
found in younger patients. This GBM subtype is comparable to the primary GBM subtype in that
it arises de novo, with no previous astrocytoma precursor occurrence, and about 30% PTEN
mutation rate. It shares characteristics of secondary GBM, where both have greater than 30%
rate of the TP53 mutation, and do not tend to occur in older adults.13 It also presents with low
expression or mutations of neurofibromin (NF-1), a gene related to a hereditary skin condition.
A fourth subtype has been classified due to its lack of similarities with the previous three
subtypes. Neural GBM presents with no outstanding genetic amplification or mutation rates,
differentiating itself from the others.
1.3 Current Treatment
Currently, the standard method of treatment for GBM begins with maximal surgical
resection of the tumor, followed by concurrent radiation and chemotherapy.23 Because GBM
penetrates surrounding tissues, surgical resection is unlikely to remove the tumor cells with
comfortable margins, and further treatment methods must be used. Most often, a more
recently approved drug, temozolomide ((8-Carbamoyl-3-methylimidazo(5, 1-d)-1, 2, 3, 5-
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tetrazin-4(3H)-one), TMZ) is administered as a chemotherapeutic agent. Temozolomide is a
prodrug that undergoes spontaneous hydrolysis into the active metabolite 5-(3-methyl)-1triazen-1-yl-imidazole-4-carboximide (MTIC). This oral alkylating agent works by promoting
methylation most often at the O6 position on guanine, initiating a sequence of DNA mismatchrepair events, leading to apoptosis 24,25. TMZ has between 96 and 100% bioavailability when
delivered orally, and was approved in 1999, since being the primary choice for GBM patients. It
is usually administered at 75mg/m2 daily with concurrent radiotherapy (RT) for 6 weeks,
followed by 6 more weeks of a higher dosed TMZ, at 150 mg/m2. Side effects include
myelosuppression and nausea. The median overall survival with the described method remains
at 14.6 months.2
The implantable chemotherapeutic was given great attention at the time of approval, in
1997. Carmustine (BCNU) had already been approved for systemic use, but the appeal of a local
delivery system was justified through successful preclinical trials, and then clinical data.8
Carmustine (BCNU) in the form of Gliadel ™ wafers are implanted into the resection cavity, to
administer local cytotoxic drug to the GBM cells remaining after resection. BCNU is a nitrosurea,
an alkylating drug working on the same pathway as TMZ, in which the polymeric wafers (poly
carboxyphenoxy-propane/sebacic acid anhydride [PCPP:SA] wafers containing 3.85% BCNU)
release BCNU for approximately 3 weeks.26 Polymeric drug delivery has been an emerging
approach to cancer treatment, where local delivery of controlled release systems can be used to
allow for higher drug concentrations at the tumor site, as well as reduce toxic systemic effects27.
At the time of development of polymeric delivery systems, carmustine (BCNU) was the most
effective form of chemotherapy for gliomas, and thus chosen for local delivery. PCPP:SA wafers
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have shown to allow for controlled sustained release and biodegradation via surface erosion.
Using systemic free BCNU, patient cell counts can take weeks to recover before the next dose
can be administered. These wafers allow for drug to be delivered over multiple days or weeks, in
comparison to free BCNU, which has a half-life of 15-30 minutes.8,27 Other drugs have been
incorporated and tested in PCPP:SA wafers, including temozolomide, the current standard of
treatment for GBM. TMZ impregnated wafers were even found to provide superior effects over
oral delivery of TMZ in rodent glioma studies.27 Though the Gliadel™ wafers have been proven
effective in preclinical in vivo studies, treatment with the wafers does not significantly improve
patient lifespan when translating clinically. Additionally, BCNU used for local delivery of
chemotherapy has been said to produce high interstitial drug concentration, while data has
shown minimal penetration of the resection cavity wall, to depths of approximately 1mm.28
BCNU wafers are not currently used in many centers due to side effects such as delayed wound
healing, intracranial edema and infection, CSF leakage and seizure, however are still generally
regarded as safe.2
In addition, bevacizumab was approved for treatment of recurrent glioblastoma in 2009.
Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth
factor (VEGF), and is also approved for use in other human tumors, such as non-small-cell lung
cancer.10 Progression of glioma growth has been shown to be mediated highly by tumorassociated blood vessels, and human glioblastomas have shown to overexpress angiogenic
growth factors, compared with normal brain tissue.29 A Phase II clinical study done, leading to
approval, shows that bevacizumab as a single-agent has significant antiglioma activity, as well
as significantly effecting the vascular permeability and decreasing cerebral edema.30
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CHAPTER 2
BARRIERS TO TREATMENT & STRATEGIES TO OVERCOME BARRIERS
Various systemic drugs have been used as treatments in patients with GBM, several barriers to
providing effective treatments remain, include crossing the blood-brain barrier (BBB) and
chemotherapeutic resistance.
2.1 The Blood-Brain Barrier
It is estimated that less than 2% of small molecule drugs, and no large molecule drugs
or genes will cross the blood-brain barrier (BBB).28 The BBB exists to regulate transport of
essential nutrients and to protect the brain from neurotoxins. It is a cellular barrier that
regulates ionic concentrations to allow for synaptic signaling in the brain, while also preventing
entry of cells and large molecules via tight junctions between endothelial cells.11 Molecules can
still cross the BBB through various mechanisms such as saturable transport, transmembrane
diffusion, adsorptive endocytosis, and other extracellular pathways31 (Banks, 2009). Most drugs
have been found to cross the BBB through passive diffusion or saturable transport, dependent
on physiochemical properties of substances including charge, molecular weight and
hydrophobicity. Lipid soluble drugs with low molecular weight are favorable for diffusion,
whereas water soluble drugs tend to transverse using transport proteins. However, various
efflux transport systems exist to remove unwanted substances that traverse the BBB using
passive diffusion. A largely studied efflux pump, P-glycoprotein (ABCB1, MDR1a), has been a
persistent challenge in drug delivery due to its efficacy in removing small molecules from the
brain.31 A wide variety of ATP-dependent substrates are recognized by ABCB1, allowing for drug
resistance to occur when these drugs are pumped out of cell through efflux pumps, reducing

10

cytotoxicity and drug efficacy.32 In 1994, a knockout MDR1a mouse study found that Pglycoprotein is a major component of the BBB, after finding greatly increased administered drug
concentrations specifically in the brain, compared with normal mice.33 Inhibitors of the action of
ABCB1 efflux proteins have been used clinically, where they have shown to allow for increased
drug concentrations in some cases, but have failed to reverse multidrug resistance in solid
tumors. Two products, elacridar and tariquidar, have been approved for use as ABCB1 inhibitors,
but complete inhibition of ABC-transport proteins at the BBB is even more difficult than in other
tissues.11,34
The BBB has been a consistent challenge in creating effective delivery systems for
therapeutics. Nanotherapeutics currently in research are being designed with this challenge in
mind, working towards creating targeted systems. However, all nanoparticles (NPs) currently
approved are considered first generation NPs and rely on diffusion and passive targeting of
tumor tissue via enhanced permeability and retention (EPR) effect.35,36 Fenestrated capillaries
exist in areas of rapidly and poorly grown vessels, due to increased VEGF expression and
angiogenesis.37,38 The leaky nature of the vasculature creates an interrupted BBB in the tumor,
which should allow for an increase in drug or therapeutic concentration in the glioma tissue.
However, it is possible that the leaky vasculature does not allow for therapeutically relevant
increases in drug concentration. Séhédic et al. agrees that the EPR effect is unlikely to be
efficient, due to the dense brain matrix and increased interstitial fluid pressure preventing
diffusion.39 Furthermore, glioma cells tend to easily travel outside the tumor to other normal
regions of the brain. This metastasis not only makes the glioma more difficult to treat, but also
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reduces the quantity of drug reaching tumor cells in the intact regions of the brain with perfectly
functioning BBB.11
2.2 Chemotherapeutic Resistance
Glioblastomas have been found to have either inherent resistance to chemotherapeutic
agents, or develop resistance during treatment. Drug resistance in GBM patients has been
attributed in part to the (O)6-methylguanine-DNA-methyltransferase (MGMT) gene. The MGMT
gene codes for the MGMT protein that removes alkyl adducts at the O(6) position of guanine, as
a natural repair mechanism to
prevents apoptosis due to DNA
crosslinking.40 Temozolomide
promotes the addition of alkyl
groups most frequently to the
O(6) position of guanine, but
also less often at the N(7)guanine and N(3)-adenine
positions, in order to cause
DNA damage and programmed
cell death.25,41 The damage

Figure 3. Schematic of MGMT/TMZ mechanism. TMZ, a DNA alkylating
agent, methylates DNA at the O6 position on guanine, resulting in DNA
damage and apoptosis. MGMT, a DNA repair protein, removes alkyl
adducts from the O6 position of guanine.

done from temozolomide is reversed or refuted due to upregulation of MGMT in GBM cells. Not
only is MGMT upregulated due to the disease state, but it has been found that the TMZ
mechanism of action causes inactivation of MGMT, which in turn leads to increased synthesis of
MGMT protein de novo, in order to restore the natural DNA repair mechanism. TMZ, as well as
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other alkylating agents, have therefore been found to acquire a large amount of resistance
when used for therapy, due to the cells upregulation of MGMT and their ability to respond to
the TMZ-caused damages by further increasing MGMT production.24 The restoration of MGMT
by de novo synthesis occurs within hours, making the timing of TMZ dosing predictive of the
therapeutic success.24 A continuous TMZ dosing schedule increases the exposure and depletes
MGMT optimally, reducing the possible resistance mechanism.42 TMZ has also been found to
induce EGFR amplification, a key agent in GBM formation, which allows for resistance
development due to tumor progression during treatment.43 Moreover, DNA lesions induced by
TMZ are found to activate the p53 pathway, and patients with wild-type, rather than mutant
p53 often found in secondary GBM, are found to respond more favorably to the treatment.24
Epigenetically, silencing of MGMT via promoter methylation has been found to be
correlated with longer patient survival when treated with alkylating agents. Methylation of
MGMT is only found to occur naturally in 30-60% of GBM cases.25 In a retrospective study done
by Donson et al., the inherent silencing of the MGMT gene provides better clinical outcomes for
pediatric patients when treated with TMZ (P=0.007), but shows to more strongly correlate with
longer patient survival regardless of treatment (P=0.0005), suggesting it may have more to do
with tumor progression than just the resistance to TMZ.44 Currently, attempts to overcome
MGMT overexpression are being investigated by methods including using O6-benzylguanine as a
pseudosubstrate for MGMT, and using RNA interference to silence the MGMT gene.45,46
Resistance occurs further due to poly(ADP-ribose)polymerase-1 (PARP-1), a baseexcision-repair gene with activity that repairs lethal lesions (N7-guanine and N3-adenine) and
repairs damage caused by TMZ. When PARP-1 is disrupted, cytotoxicity increases in response to
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the methylation from alkylating drugs.41 The PARP-1 gene has been shown to have increased
activity in GBM cells treated with TMZ, likely in response to the DNA damage. Glioma stem cells
also appear to play a role in chemoresistance in GBM. Glioma stem cells sampled from highly
resistant GBMs express multidrug resistance protein-1 (MDR1), and at higher levels than do
differentiated glioma cells. These non-differentiated stem cells therefore display more
resistance to chemotherapeutic agents, such as TMZ, furthering the proliferation of the tumor.47
Beier et al. explains that cancer stem cells can be intrinsically resistant, where treatment doesn’t
affect the tumor growth and recurrence is soon after treatment, or extrinsically resistance,
where cancer stem cells survive in brain parenchyma and allow for distant recurrences.48 These
mechanisms together can allow for highly resistant and difficult to treat glioblastomas.
2.3 Immunotherapy
The research community has been addressing challenges in treating glioblastoma from
many different angles. A few critical attempts have been in immunotherapy, gene therapy and
various drug delivery modalities. Monoclonal antibodies have been researched for the purpose
of inhibiting oncogene activity, and providing support to the body’s immune system. Erlotinib,
genfitinib, cetuximab, and bevacizumab have been used in phase II clinical trials to inhibit EGFR
overactivity in high grade gliomas.30,49–51 Results have shown that as single agents, these
biologics are not effective in treating glioblastoma with the exception of bevacizumab, showing
significant antitumor activity compared to historical controls.30,52 Sorafenib has been researched
in phase I clinical trials to inhibit PDGF receptor-b, with results proving safety.53,54 However, one
phase II trial that has been completed produced only 9% of patients with 6-month progression
free survival, rendering sorafenib to have limited efficacy in treating GBM.55 Pembrolizumab,
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another immunotherapy, is in phase I/II clinical trials currently. It is used to inhibit the
overexpressed programmed death ligand PD-L1 from providing protection to tumor cells in GBM
patients, though results are not reported (NCT02530502). The increased expression of PD-L1
inhibits recognition and elimination by T-cells, and inhibition of this PD-L1 using pembrolizumab
may assist the immune system in fighting off cancer.
2.4 Gene Therapy
Gene therapy includes both the delivery of genes to be integrated into the patients’
cells, and the delivery genetic material to affect a patient’s gene expression. The delivery of
genes is traditionally to replace either missing or mutant genes to correct disorders, and can be
delivered using viral or non-viral vectors. The delivery of genetic material regards using RNA
interference (RNAi) to affect the expression of DNA and proteins,
2.4.1 Viral Gene Delivery
Viral vectors have been studied and in clinical trials for years as delivery vehicles for
genes into mammalian cells. The first clinical trial publishing gene therapy for glioma treatment
used retrovirus-mediated HSV thymidine kinase (HSV-TK) and ganciclovir, beginning in 1992
(NCT00001328).56,57 Certain viruses, considered neurotropic, have a tendency to interfere with
and selectively bind with neurons and glial cells. These neurotropic viruses, such as HSV1,
adenoviruses and paramyxoviruses have been specifically targeted as vectors for treatment of
gliomas58–60. Various viral vector methods have been studied such as suicide gene therapy,
which can be used to produce transcription enzymes that convert non-toxic prodrugs into lethal
active compounds. Other virally transported gene therapy attempts include oncolytic,
immunomodulatory and tumor suppressor gene therapy.61 Phase III clinical trials done by Rainov
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et al. tested the effects of combining retrovirus mediated herpes simplex virus-thymidine kinase
gene (HSV-TL) with ganciclovir (GCV) in 248 patients with newly diagnosed GBM. The HSV-TK
gene converts prodrug GCV to its active form GCV-triphosphate, to inhibit DNA replication and
cell division of infected proliferative cancer cells. The group found that despite safety, low
transfection efficiency in humans remains a challenge in producing significant differences in
treatment groups (HSV-TK/GCV combined with chemotherapy and radiation) compared to those
treated solely with chemotherapy and radiation.62 Another clinical trial completed phase 2a in
2010, using adenovirus-mediated HSV- thymidine kinase (AdV/TK) therapy combined with antiherpetic valacyclovir and radiation for the treatment of glioblastoma. Results showed that the
treatment increased overall survival by 3.6 months compared to current standard of care.63
Amphitropic retroviral replicating vector (RRV) Toca 511, developed by company Tocagen has
their regimen in phase 2 clinical trials, where the Toca 511 virus infects and delivers the cytosine
deaminase (CD) gene, and then orally taken Toca FC delivers fluorocytosine (FC) (NCT02414165).
The CD enzyme produced allows for the FC prodrug to become an active anticancer drug (5-FU)
and kill cancer cells, and has been concluded to be safe for intravenous administration in phase I
trials. (NCT01985256).64 Though viral vectors have been studied extensively, they have only
resulted in marginal increase overall survival and have yet to achieve FDA approval after
decades of study.
2.4.2 Non-viral Gene Delivery
Due to the inability to translate virally delivered therapeutics to market, many
researchers have shifted focus to non-viral vectors. Recently, much research has gone into
studying nanoparticles for the systemic delivery of drugs or genes. Nanoparticles (NPs) have
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been of great interest for the delivery to the brain, with aims of crossing the blood brain barrier.
They allow for conjugation of nucleic acids, homing peptides, or targeting ligands. Major types
of nanoparticles used for delivery in glioblastoma include polymeric nanoparticles, liposomes
and lipid nanoparticles.
Polymeric nanoparticles
Polymeric nanoparticles are widely studied due to their multifunctionality, and their
ability to improve solubility, stability and biodistribution of therapeutics they carry.65 They tend
to be safer and more predictable than viral vectors. Aside from the array of naturally available
polymers, there are endless possibilities in the field of synthetic polymers. The ability to create a
nanoparticle to fit the biodegradation and drug-release profile needed for specific applications is
appealing for drug and gene delivery alike. For delivery to brain tumors, polymeric NPs have
potential capability to transport substances across the BBB. A few main types of polymeric NPs
used for targeting glioblastoma include dendrimers, poly(β-amino ester) (PBAE) and
polyethyleneimine (PEI).
Dendrimers are highly branched synthetic polymers that have been used for the delivery
of nucleic acids, specifically siRNAs. They also have the ability to incorporate drug delivery or
imaging agents for additional therapeutic benefit. Poly(amidoamine) (PAMAM) dendrimers have
been of interest because they can conjugate with siRNAs and targeting ligands such as folic acid
for increased delivery specificity, and have been found to cross the BBB. A study by Waite et al.
conjugated cyclic RGD (arginine-glycine-aspartic acid) peptide to PAMAM dendrimers, as a
targeting moiety to cellular integrins. They then conjugated siRNAs to the complex and delivered
to U87 glioma cell spheroids, with findings that their delivery system was able to penetrate
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malignant spheroids and efficiently produce gene silencing.66 One critical limitation of PAMAM
dendrimers for clinical translation is cytotoxicity due to their high positive surface charge.
Studies have shown that PAMAM dendrimers exhibit neurotoxicity by inducing autophagy in
glioma cells resulting in cell death.67 Strategies to mitigate this effect include reducing the
surface charge through acetylation or functionalization using PEG.
One group used a poly(β-amino ester) nanoparticle conjugated with DNA coding for the
herpes simplex virus-thymidine kinase gene (HSV-tk), and ganciclovir (GCV) for therapy in glioma
cell lines. They found that the cell lines (9L and F98) in vitro had 100% cytotoxicity compared the
cells transfected with green fluorescent protein (GFP), an innocuous gene, and also treated with
GCV. When delivered in vivo, they found that glioma-bearing rats had a significant survival
benefit over control rats.68 Another group used the biodegradable PBAEs conjugated to DNA and
achieved over 60% transfection in human brain tumor initiating cells (BTICs) in nude mice, and
significant specificity for transfection in tumor tissue over normal brain tissue. PBAEs show
promise as a non-viral vector for genes in brain tumors, with lower immunogenicity and higher
transfection efficiency.69
Polyethyleneimine (PEI) is another commonly used synthetic nanoparticle that can
effectively complex with nucleic acids, such as siRNA and DNA. PEI is a cationic polymer that can
be modified with hydrophobic polymers or targeting ligands for combination drug delivery or
targeted delivery, respectively. PEI can easily penetrate the cellular membrane, and escape the
endosome using proton buffering. Additionally, to reduce the cytotoxic effect of PEI and enable
attachment of targeting ligands, poly(ethylene glycol) (PEG) conjugation is commonly applied to
PEI. RGD ligands and PEG have been conjugated to PEI for the delivery of plasmid DNA. Zhan et
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al. found that this complex allowed for efficient gene transfection in U87 glioma cells in vitro
and in vivo.70
Cationic liposomes and lipid nanoparticles
Liposomes have been studied extensively as a non-viral vector for the use of drug and
gene delivery. Cationic lipids tend to electrostatically complex with DNA to form positively
charged lipoplexes.71,72 Though gene delivery via liposomes has been accepted as safe,
liposomes have not proven highly effective for gene transfection in humans. However,
liposomes have the ability to carry hydrophobic or hydrophilic molecules within their vesicular
structure, making them good vehicles for drug delivery. In delivery to tumors, it has been found
that cationic liposomes accumulate in tumor tissues due to their positive charge. To deliver
across the BBB to brain tumors, one group used focused ultrasound to deliver doxorubicin
loaded cationic liposomes (DOX-CLs), and then allowed DOX-CL to target C6 glioma tissue in
vivo. They found that the delivery system increased animal survival time and decreased
progression of glioma growth, compared with free DOX.73 A study by Calcagno et al. developed a
cationic liposome (scL-TMZ) for the delivery of TMZ to glioblastoma cells (U87R). They found
that the liposome increased the sensitivity of resistant cells to TMZ treatment compared to
when treated with free TMZ.74 The only synthetic nanomedicine to reach clinical trials for
systemic delivery to data are cationic liposomes.61
Solid lipid nanoparticles have been in laboratories since the 1990’s, and are studied in
delivery to the brain in part due to their hydrophobic, low molecular weight characteristics,
making them favorable for transport across the BBB.11 Lipid NPs have advantages over other
delivery systems, such as good biocompatibility, controlled drug release and minimal
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cytotoxicity. They also have the ability to deliver otherwise highly insoluble lipophilic drugs
across the BBB.75 Nanostructured lipid carriers (NLCs) are composed of solid and liquid lipids,
allowing for greater drug loading due to an imperfect crystal structure. A study by Chen et al.
loaded TMZ and pGFP into NLCs (made from soya lethicin, DDAB and tween 80), to determine
feasibility in delivering drug and gene through the mouse tail-vein to human glioma tumors
(formed subcutaneously with U87 cells). They found significant increase in gene transfection
compared to positive control Lipofectamine 2000, and significantly increased cytotoxic effect
compared with free TMZ.76 One group investigated the ability of polymeric NPs, solid lipid NPs
and nanostructured lipid carriers to deliver TMZ to glioblastoma tumors. They developed each
nanoparticle to be loaded with TMZ and evaluated the anti-tumor activity in vitro and in vivo,
and found that the nanostructured lipid carriers displayed the most significant glioma growth
inhibition.75
2.4.3 RNA interference
RNA interference (RNAi) has become the gold standard for the silencing of genes since
its discovery in 1998.77 RNAi can be achieved by using plasmid DNA (pDNA), small hairpin RNA
(shRNA) or short interfering RNA (siRNA). MicroRNAs (miRNAs) are another interference method
used, similar to siRNA in length and non-coding nature, but lacking the limited specificity to one
mRNA. Most commonly focused on for gene silencing is siRNA, due to its specificity and proven
safety and efficacy.78 Interference occurs when the antisense siRNA will bind to a target mRNA
to induce nucleolytic degradation of a specific gene, and prevent translation of a desired
protein. In cancer, siRNAs have been found to be useful in silencing proliferative genes, or
oncogenes, that allow for uncontrolled growth of tumors, as well as showing promise in
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sensitizing cancer cell to chemotherapeutics.78 Initially, local delivery of siRNAs to the tumor was
relied on for therapeutic effect, however research has progressed in creating delivery systems to
protect the siRNA stability from degradation by nucleases in the body using carriers such as gold
nanoparticles, polymeric micelles and liposomes.77 Specificity and efficiency of siRNA have been
proven in vitro, in vivo and through clinical trials, but not without unwanted effects such as
nonspecific inflammation and challenges such as siRNA instability and producing controlled
siRNA release from the delivery vessel.77 Yoo et al. has researched an iron oxide nanoparticle
conjugated chlorotoxin peptide (CTX) for targeting GBM cells (T98G) and to siMGMT for
silencing MGMT. They found that their nanoparticle increased sensitivity to TMZ and
cytotoxicity in vitro and in vivo, but were unable to distinguish if this effect was due to CTX or
the MGMT silencing.79 Wang et al. published work delivering siRNAs to silence EGFR and βcatenin in GBM cells (U-87 MG), where they found that cell proliferation was reduced when
treated with siRNAs targeting β-catenin and β-catenin + EGFR, but not EGFR alone.52 Clinical
trials using siRNAs are few, with only a handful attempted for the treatment of tumors. Clinical
trials administering siRNAs for the direct silencing of genes for GBM treatment have yet to be
attempted.80,81 The use of RNA interference can be very valuable in reducing the expression of
genes and proteins in certain cells, rather than introducing new or improved genes into the
genome.
2.5 GBM Treatments in Clinical Trials
Previously discussed therapies in clinical trials, as well as additional treatments for
glioblastoma currently in clinical trials are displayed in Table 1. Most treatments in clinical trials
currently are virally delivered gene therapies, combined with cytotoxic drugs. However,
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therapies include a vaccine, neural stem cell injections, and an MGMT pseudosubstrate. A
survivin peptide vaccine (SurVaxM) treatment is currently in clinical trials with attempts to treat
gliomas by eliciting an immune response to the overexpressed survivin protein in GBM cells. In
phase 2 trials, SurVaxM has been used in combination with TMZ, Sargramostim, and Montanide
ISA 51 VG, in order to kill cancer cells, restore blood cells suppressed due to the therapy, and as
an adjuvant to human vaccine, respectively. (NCT01250470)82,83 In vivo studies show that siRNA
knockdown of survivin induces apoptosis in GBM tumors and significantly inhibits glioma
growth.84
A phase I clinical trial implanted neural stem cells (HB1.F3) expressing E. coli cytosine
deaminase (CD) into the resection cavity of high grade glioma tumors. Oral 5-fluorocytosine (5FC) was given, with the intent of the expressed CD enzyme to convert 5-FC to the lethal
compound 5-FU. This first in man study concluded safety and feasibility to target brain tumors,
as well as produce a local cytotoxic effect (NCT01172964).85 Phase II clinical trials are currently
recruiting recurrent GBM patients for the study of SGT-53, a cationic liposome encapsulating
wild-type p53 tumor suppressor gene in a plasmid backbone, in hopes that the delivery of
normal p53 gene in combination with TMZ will provide longer overall survival (NCT02340156).
SGT-53 has shown promise in mice, where sensitivity to TMZ was shown to be enhanced with
treatment.86 O6-benzylguanine (O6-BG) was developed as a substrate inhibitor of MGMT,
working by binding to MGMT and diminishing the enzyme activity. O6-BG has been and is still in
clinical trials, in combination with alkylating agents TMZ and BCNU, and has shown thus far to
increase sensitivity of the tumors to the alkylating agents.45 A phase II clinical trial has been
completed using O6-benzylguanine in combination with temozolomide in pediatric patients with
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high-grade gliomas, and it was concluded that the combination did not achieve the target
therapeutic response rate.45,24 However, another phase II clinical trial of TMZ plus O-6BG in
adults concluded that the combination restored sensitivity to TMZ.87

VECTOR

MAIN
THERAPEUTIC
AGENT

Liposome

SGT-53

Retroviral
Replicating
Vector

Toca 511/ Toca FC

Adenovirus

AdV/tk

Adenovirus

Recombinant
adenovirus-p53
SCH-5850

Retrovirus

MGMTP140Kencoding retroviral
vector

Neural Stem
Cell

HB1.F3

MECHANISM
Introduce wild-type tumor
suppressor p53 gene to sensitize
cells to TMZ
Introduce yeast cytosine
deaminase (CD) gene to convert
prodrug 5-FC to lethal compound
5-FU
Herpes thymidine kinase
delivered to cancer cells, then
anti-viral valacyclovir targets
expressing cells
Introduce wild type tumor
supressor p53 gene into brain
cells, into resection cavity
Genetically modified peripheral
blood stem cells may prevent
side effects (myelosuppression)
from chemotherapy as O6benzylguanine prevents TMZ
resistance caused by MGMT
overexpression
Neural stem cells expressing E.
coli cytosine deaminase (CD)
gene implanted into resection
cavity and prodrug 5-FC is
converted to lethal 5-FU

COMBINATION

CLINICA
L TRIAL
PHASE

REFERENCES

TMZ
(chemotherapeutic)

Phase II

NCT0234015686

Oral 5-FC (cytotoxic)

Phase II

NCT0241416564

Valacyclovir (antiviral)

Phase
IIa

NCT00589875 63

Conventional
surgery

Phase I

NCT00004080 88

-O6-benzylguanine
(MGMT inhibitor)
-TMZ
(chemotherapeutic)
-Radiation

Phase I

NCT01269424

Oral 5-FC (cytotoxic)

Phase I

NCT01172964

Phase II

NCT02455557,

Phase II

NCT00275002,

Vaccine

SurVaxM

Survivin vaccine causes body to
elicit immune response to cells
expressing survivin

-Sargramostim
(biological)
-TMZ
(chemotherapeutic)
-Montanide ISA 51
VG (drug)

MGMT
pseudosubstrate

O(6)benzylguanine

O(6)-BG irreversibly inactivates
MGMT in order to improve
effectiveness of TMZ

TMZ
(chemotherapeutic)

Table 1. Current state of clinical trials for the treatment of glioblastoma multiforme.
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CHAPTER 3
RESEARCH AIMS
3.1 Objectives
The current treatment options for glioblastoma do not effectively improve the disease, and
great improvement is needed to extend patient lifespan. The overall goal of this research is to
develop a multifunctional nanotherapeutic for the treatment of malignant glioblastoma. It is
hypothesized that combinatorial delivery of temozolomide and siRNA targeting MGMT will
sensitize tumor cells to TMZ, a DNA alkylating agent, due to the knockdown of MGMT. This
study will focus on nucleic acid delivery for the future combination treatment with TMZ.
3.2 Multifunctional Nanotherapeutic Design
The polymeric micelle PgP, or poly(lactide-co-glycolide) -graft-polyethyleneimine, is a novel
polymeric system developed by our lab, with the potential to deliver nucleic acids and drugs.
The cationic, amphiphilic copolymer assembles spontaneously into micelles in an aqueous
environment. As represented in Figure 4, the hydrophobic PLGA constructs the core, and the
positively charged polyethyleneimine (PEI) makes up the shell of the micelle. PgP is designed to

PEI150-250 nm

150-250 nm

Figure 4. PgP micelle schematic. The micelle formation of poly(lactide-co-glycolide)-graft-poly(ethylenimine), PgP.
Hydrophobic PLGA orients into the core and the hydrophilic PEI orients to the shell of the micelle formation. The cationic
polyplex then allows for delivery of both drug and siRNA for maximum therapeutic effect.

24

be complexed with negatively changed nucleic acids to form a polyplex held together with
strong electrostatic interaction between the nucleic acids (such as siRNA) and the PEI shell. The
hydrophobic core allows hydrophobic or lipophilic drugs to be loaded within for delivery. The
approximately 200nm polyplex is strategically between the sizes of kidney and liver excretion,
designed to allow the polyplex to avoid clearance and stay in circulation when administered
intravenously. When the polyplex enters circulation, it can be targeted to cancerous tumors via
the enhanced permeability and retention (EPR) effect, as described previously. Once the
polyplex makes its way into the tumor cell, it can be taken up into the cell via endocytosis, and
escapes by means of the proton sponge effect. Due to the cationic nature of the polyplex, the
endosome will swell in attempt to maintain homeostasis, and eventually rupture, allowing the
contents to release into the cytosol, and siRNA to escape.
3.3 Study Design
Determining efficacy of this polyplex includes determining the stability of the PgP when
conjugated with siMGMT. Once the stability is determined in vitro, the cytotoxicity of the
polyplex in human glioblastoma (T98G) cells will be assessed. The efficacy of siRNA delivery, as
well as the reduction in gene expression and protein production will be evaluated in vitro. The
stability of the polyplex will be evaluated by presenting the polyplexes to various physiologicallike conditions in vitro, such as serum and ribonucleases. Given the polyplex is proven stable in
physiological conditions, the cytotoxicity is minimal, and the polyplex proves effective in siRNA
delivery, the delivery system will be introduced to mice, for in vivo studies of efficacy. In vivo
studies first involve producing a xenograft glioblastoma model. This will involve introducing
T98G cells, as studied in vitro, into the brains of nude mice. Determination of the tumor growth
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can be made with analysis of the brain tissue ex vivo, on the macroscopic and microscopic levels.
Confirmation of tumor cell growth within the mice can allow this project to move forward to
studies of the polyplex biodistribution and therapeutic efficacy. Therapeutic efficacy of
PgP/siMGMT will be evaluated in mice by injecting polyplex to the tumor site, then removing
tumor tissue for protein and RNA extraction. Comparing untreated control tumor tissue with
treated tissue will allow knockdown efficiency in vivo to be analyzed. Future studies can include
assessing the antitumor effect of MGMT knockdown when combined with TMZ.
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CHAPTER 4
MATERIALS & METHODS
4.1 Materials
Poly(lactide-co-glycolide) (PLGA, 4KDa 50:50) was obtained from Durect Corporation, Pelham,
AL. with a carboxylic end group and 25 kDa branched polyethyleneimine (bPEI) was purchased
from Sigma-Aldrich, St. Louis, MO. All siRNAs were purchased from GE Healthcare Dharmacon
(Lafayette, CO). siRNA targeting MGMT (O6-methylguanine-DNA methyltransferase, NCBI
Reference Sequence: NM_002412.4, siMGMT) was custom-synthesized. siGENOME nontargeting siRNA #5 (siNT) was also purchased and used as a negative control siRNA. Additionally,
siNT with a fluorescein label (FI-siNT) at the 3’ end of the anti-sense strand was synthesized and
used in fluorescence experiments. The T98G cell line was obtained from ATCC in Manassas, VA.
LysoTracker™ Blue DND-22 and Mouse monoclonal anti-MGMT antibody (clone MT3.1), Halt™
Protease & Phosphatase Inhibitor Cocktail, Pierce BCA protein assay kit, SuperSignal™ West Pico
Chemiluminescent Substrate, and the cDNA Reserve Transcription Kit were obtained by Fisher
Scientific. Mouse monoclonal anti-β-actin antibody (1:5,000) was obtained from Santa Cruz
Biotechnology, Dallas, TX. Goat anti-mouse secondary antibody was obtained from Southern
Biotechnology, Birmingham, AL. Immun-Blot® PVDF membranes were obtained from Bio-Rad
Laboratories, Hercules, CA. Phenylmethanesulfonyl fluoride and Thiazolyl blue Tetrazolium
Bromide (TBTB) were obtained from Sigma-Aldrich. Taqman® Gene Expression Assays Thermo
Fisher Scientific, Waltham, MA. Nude athymic mice (Foxn1nu) were obtained from Envigo.
Buprenorphine was obtained from Hospira, Inc. Hamilton syringes were obtained from Hamilton
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Company, Reno, NV. Nucleospin RNA/Protein kit was obtained from Machery-Nagel, Bethehem,
PA.
4.2 Synthesis of poly(lactide-co-glycolide)-graft-poly(ethyleneimine)
The cationic, amphiphilic copolymer poly(lactide-co-glycolide)-g-polyethyleneimine (PgP) was
synthesized as previously described 89 using 4 kDa poly(lactide-co-glycolide) (PLGA, 50:50) with a
carboxylic end group and 25 kDa branched polyethylenimine (bPEI). PgP was purified using a
dialysis membrane with molecular weight cut-off (MWCO) of 50,000 Da. PgP was then
centrifuged at 5,000 rpm for 10 minutes in order to remove excess PLGA precipitate, and
lyophilized for storage.89
4.3 Gel shift assay
In order to determine the optimal N/P (amine: phosphate) ratio necessary for complete binding
of the PgP and free siRNA complex, a gel shift assay was performed. A 2% agarose gel was
prepared with a 12-well comb. PgP was complexed with siRNA in deionized water at various N/P
ratios ranging from 0 to 25 and incubated for 30 minutes at 37°C. Loading dye was added to the
samples and each was loaded into the gel, then samples were electrophoresed at 100V for 25
minutes. It was stained with 0.2% ethidium bromide in water for 10 minutes and then rinsed
with water for 15 minutes on a shaker. The ChemiDoc-It2™ system was used to image the gel
using an ethidium bromide filter and UV light (UVP, Upland, CA).
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4.4 Characterization of PgP/siMGMT
To evaluate the particle size and surface charge of polyplexes, PgP was complexed with siMGMT
(20 µg) at N/P ratio of 30:1 and 60:1. The N:P ratios were identified from gel shift assay. The
polyplex was measured in using a Zetasizer (Malvern Zetasizer ZS DLS-Zeta) instrument that
measured particle size, polydispersity index (PDI), and surface charge (zeta potential).
4.5 Cell culture
The human glioblastoma cell line T98G was cultured in specified growth media supplemented
(EMEM) with 10% fetal bovine serum (FBS) and 1% antibiotic (100IU/ml penicillin/100µg/ml
streptomycin), and grown in an incubator at 37°C with 5% CO2.
4.6 PgP-mediated MGMT silencing
The efficiency of siMGMT transfection and MGMT silencing was quantified in T98G cells.
Polyplexes were formed by complexing PgP with siMGMT (100 nM) at N/P ratios of 30:1, 60:1,
and 80:1 in sterile deionized water at 37°C for 30 min. siMGMT complexed with Lipofectamine
2000 was used as a positive control. Additionally, at each N/P ratio, siNT was complexed with
PgP as a negative control for comparison of each treatment. T98G cells seeded at 1x105 cells
per well and cultured in 12-well plates were washed three times with media and incubated with
PgP polyplexes for 24 hours in media containing 10% FBS, after which, cells were again washed
three times with media and incubated with complete media containing 10% FBS for another 24
hours. 48 hours post-transfection, protein or RNA was extracted from the cells for western blot
or real-time PCR analyses, respectively, as described in the following sections.
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To analyze the knockdown of MGMT on the protein level, western blot was performed.
48 hours post-transfection, cells were washed with 1X cold PBS and lysed with ice cold RIPA
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, and 1% NP40)) containing protease inhibitor, phenylmethanesulfonyl fluoride and Halt™ Protease &
Phosphatase Inhibitor Cocktail. Total protein concentration was determined using the Pierce
BCA protein assay kit via the manufacturer’s instructions. 3 µg of protein lysates were resolved
by SDS-PAGE using polyacrylamide gels and transferred onto Immun-Blot® PVDF membranes.
PVDF (polyvinylidene fluoride) membranes were blocked for 1 hour in Tris-HCl-buffered saline
containing 0.1% Tween-20 (TBS-T) and 5% milk. Following blocking, membranes were incubated
with mouse monoclonal anti-MGMT antibody (1:500) or mouse monoclonal anti-β-actin
antibody (1:5,000) overnight at 4°C then washed four times with TBS-T and incubated in
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:2,000 or 1:10,000)
for one hour. SuperSignal™ West Pico Chemiluminescent Substrate (Fisher Scientific) was used
to detect immunoreactive bands which were subsequently imaged using the ChemiDoc-It2™
Imager.
To analyze MGMT knockdown on the mRNA level, RT-PCR was used. After 48 hours
transfection, total RNA was extracted from cells using the RNeasy® Plus Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. The concentration and purity of
isolated RNA was determined using the Biotek plate reader and Take3 Micro-Volume Plate.
Isolated RNA (100 ng) was reverse-transcribed using the High-Capacity cDNA Reserve
Transcription Kit with MultiScribe® Reverse Transcriptase (RT) and RT Random Primers. Realtime PCR was performed using a Rotor Gene Q thermal cycler (Qiagen) with predesigned
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Taqman® Gene Expression Assays for MGMT (Hs01037698_m1), and the endogenous control,
18S (4319413E), combined with Taqman® Gene Expression Mastermix according to the
manufacturer’s instructions. The threshold cycle (CT), the cycle number at which the
fluorescence generated within the reaction crosses the threshold line, was determined. Relative
ΔΔ

mRNA expression of MGMT was calculated using the 2- CT method. Minus RT reactions were
also performed to ensure that there was no significant genomic DNA contamination.
4.7 Cytotoxicty of PgP/siMGMT
To evaluate if the polyplex caused toxicity to the cells, a cytotoxicity study was performed. T98G
cells (1X105 cells/well) were cultured in 24-well plates and allowed to attach overnight. PgP
polyplexes were formed using siNT (100nM) at N/P ratios of 30:1, 60:1 and 80:1, incubated at
37°C for 30 minutes. Controls consisted of untreated cells, siNT alone, and
Lipofectamine2000/siNT. Polyplexes were incubated with T98G cells for 24 hours in media
containing 10% FBS, and then washed three times with media and incubated for an additional
24 hours. At 48 hours post-transfection, an MTT assay was performed to determine cytotoxicity.
Cells were incubated with 120 µL/well of Thiazolyl blue Tetrazolium Bromide (TBTB) dissolved in
PBS at 2 mg/ml, added to 500µL media. After a 4 hour incubation at 37C, the media containing
TBTB was aspirated and 500µL DMSO was added to each well to dissolve formazan crystals.
Wells were thoroughly mixed using micropipette and 100µL from each sample was removed and
transferred into a 96-well plate. The Biotek Synergy plate reader (Winooski, VT) was used to
measure absorbance of wavelength of 570 nm in order to determine concentrations of
formazan in each well. Samples were normalized using untreated cells, and cell viability was
determined using following equation: Cell viability (%) = (OD570(sample)/OD570(control)) x 100%.
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4.8 Stability of PgP/siRNA polyplexes in various conditions
4.8.1 Heparin competition assay
To determine the stability of the PgP/siRNA polyplex, polyanion heparin was introduced to the
polyplex. First PgP/siRNA polyplexes were formed at an N/P ratio of 60:1 and incubated for 30
minutes at 37°C. Then heparin was added to the samples at various weight ratios (heparin:
siRNA) and incubated for 30 additional minutes. Control groups of siRNA alone and PgP/siRNA
without heparin were included. Weight ratios included 1, 2, 5, 10, 20, 50 and 100. Conditions
described previously were used to run the gel with 20 uL of each sample was loaded.
4.8.2 Serum and RNase protection assay
The stability of the polyplexes in the presence of serum and RNase were tested and compared
to the stability of the polyplex in water. PgP/siRNA was also compared to negative control of
siRNA alone, and known transfection reagents PEI and Lipofectamine® 2000 (LIPO). PgP/siRNA
was complexed at N/P 60:1 in water for 30 minutes at 37°C; PEI/siRNA was complexed at N/P
5:1 in water and incubated for 30 minutes; LIPO/siRNA was complexed in Opti-MEM at
manufacturer suggested N/P; and naked siRNA was prepared in water.
Samples were next exposed to 10% serum, 50% serum, or 0.1 µg RNAse A conditions and
incubated 1 hour at 37°C. After incubation, 10% SDS was used to dissociate the siRNA from
complexes, and samples were immediately run through gel electrophoresis using above
described conditions. Each sample was compared to a respective control where the serum or
RNAse conditions were replaced with a 30-minute incubation in water. The samples were
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examined by gel electrophoresis using a 2% agarose gel stained with ethidium bromide and
imaged with the ChemiDoc-It2™ Imager.
4.9 PgP-mediated intracellular uptake of siRNAs
Transfection efficiency using PgP as a delivery system was tested by first transfecting T98G cells
with fluorescently labeled siRNA (FI-siNT) and observing using fluorescent microscopy. T98G
cells were seeded in 12-well plates at 1X105 cells per well and allowed to attach overnight. PgP
was complexed with FI-siNT (100 nM), a fluorescein non-targeting siRNA, at N/P ratios of 30:1,
60:1, and 80:1 and incubated for 30 minutes at 37°C. FI-siNT alone was used as a negative
control and FI-siNT complexed with PEI (5:1) or Lipofectamine 2000 were used as positive
controls. Media (EMEM + 10% FBS) was added to each sample and then 1 mL was added to each
well. Each well contained 2 µg siRNA. After 6 hours, cells were washed three times with 1X
phosphate buffered saline (PBS) and transfection efficiency was evaluated based on density and
brightness of cell fluorescence using confocal microscope. To examine the uptake mechanism of
polyplexes, cells were stained with LysoTracker™ Blue DND-22 according to the manufacturer’s
instructions prior to imaging.
For quantitative analysis, flow cytometry via the Guava Easycyte ™ (Millipore, Darmstadt,
Germany) was used to determine transfection efficiency. Cells were trypsinized and removed
from well plates, and each sample was run through the flowcytometer. Cell populations were
gated according to fluorescence of untreated cells. A heparin wash was used to ensure that
fluorescently labeled siRNA was in fact entering the cells, rather than adhering to the cell
surface.
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4.10 Effect of MGMT knockdown on antitumor activity of TMZ
To evaluate the effect of MGMT knockdown on the cytotoxicity of TMZ, combination treatment
was performed. T98G cells were plated at 1X105 cells per well in 24-well plates and allowed to
attach overnight. PgP/siMGMT polyplexes were made at N/P ratio 60:1 and incubated for 30
minutes. Polyplexes were added to the cells, immediately followed by TMZ addition at
concentrations of 500 µM (half the IC50 value) and 1000 µM (IC50). MTT assay was performed
72 hours after transfection. Untreated cells were used as a control. Free TMZ, PgP/siNT with
TMZ, and PgP/siNT or PgP/siMGMT without TMZ were used for comparison
4.11 Generation of xenograft glioblastoma model in athymic mouse brain
All animal procedures were conducted according to NIH guidelines for the care and use of
laboratory animals (NIH publication No. 86-23, revised 1996) and approved by the Clemson
University Animal Research Committee (animal protocol number AUP 2016-080). Eight week-old
nude female athymic mice were used to create a GBM brain tumor model. Mice were
anesthetized using isofluorane gas and were arranged into a stereotactic frame. Buprenorphine
(0.1 mg/kg) was injected subcutaneously for pain before incision. An incision was made along
the sagittal plane on the scalp, the bregma was located and the point 1.5 mm to the right was
marked. A 26-guage Hamilton syringe containing 4µL of T98G cells, a total of 150,000 cells, was
assembled into the stereotactic frame and inserted 3 mm deep into the brain. The cells were
injected at a controlled flow rate of 1 mL/min and then the syringe was allowed to remain in the
injection site for 5 minutes before removal. The syringe was slowly removed and sterile bone
wax sealed the hole in the skull and the incision site was sutured.
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4.12 Biodistribution of DiR-loaded polyplexes after intratumoral injection
We first evaluated the biodistribution of polyplexes to determine whether polyplexes remain in
the tumor or diffuse out after intratumoral injection. To visualize the polyplexes, DiR was loaded
into PgP using solvent evaporation method. Two weeks post-injection of tumor cells, mice were
treated with with DiR-loaded polyplexes (DiR-PgP/siNT) for biodistribution analysis. Using the
procedure previously described, mice were anesthetized, arranged in stereotactic frame, and
injected with DiR-PgP/siNT, containing 2µg siRNA and 4µL volume. The injections were
performed at the same original injection site (1.5 mm right of bregma, 3mm deep) at a flow rate
of 1µL/min. Mice were imaged at 1 hr, 3 hr, 6 hr, 24 hr, and then every 48 hours for 10 days.
Live animals were anesthetized using isoflurane and placed into the IVIS Luminar XR in vivo
imaging system (Caliper Life Science). An excitation wavelength of 745nm and emission of
790nm was used to image the DiR loaded polyplex, to analyze the biodistribution of polyplexes.
At day 10, mice were euthanized and organs were extracted for ex vivo analysis of the complex
retention in tissues.
4.13 Knockdown efficiency of PgP/siMGMT after intratumoral injection in athymic GBM model
For knockdown efficiency analysis, mice were treated with siNT or siMGMT (2 µg, 4 µL volume)
complexed with PgP, four weeks post-injection of tumor cells. Using the procedure previously
described, mice were anesthetized, arranged in stereotactic frame, and injected with PgP/siNT
or PgP/siMGMT, containing 2µg siRNA and 4µL volume. The injections were performed at the
same original injection site (1.5 mm right of bregma, 3mm deep) at a flow rate of 1µL/min. Mice
were euthanized 72 hours post-treatment and the brain was excised and preserved in RNAlater.
A 1mm x 1mm x 2mm sized tissue sample was taken from each brain at the same location, in
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order to remove tumor tissue. RNA and protein was extracted using Nucleospin RNA/Protein kit
according to the manufacturer’s instructions. Following extraction, the RNA purity and
concentration was quantified using the Take3 plate reading system. The protein concentration
was quantified by performing BCA assay, and protein was analyzed using western blot, using the
methods previously described. The MGMT mRNA expression was evaluated by performing
reverse transcription and then RT-PCR, as described previously.
4.14 Statistical Analysis
Quantitative data were presented as mean ± SEM. Statistical analysis was performed using
either Student’s t-test or one-way ANOVA (Bonferroni’s Multiple Comparison Test). A value of
P<0.05 was considered statistically significant. All statistical analyses were examined using
GraphPad Prism 6 software.
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CHAPTER 5
RESULTS
5.1 PgP effectively binds siRNAs
The amphiphilic, cationic micelle PgP was designed to self-assemble with a hydrophobic PLGA
core, and a positively charged PEI shell, for the formation of a polyplex when bound with nucleic
acids. This gel shift assay was performed in order to determine the effective binding amine:
phosphate (N/P) ratio for PgP and siRNA. The PgP/siRNA polyplex was found to bind with
stability at N/P ratios over 15:1 (Fig. 5), where there was no detectable unbound siRNA in the
gel. Free siRNA suggests unstable or lack of binding with the PgP. A noticeable reduction in free
siRNA, and therefore a noticeable increase in bound siRNA is seen starting at an N/P of 7.5. This
finding allowed us to choose N/P ratios over 15:1 to continue forward with. In our previous
study published in Biomaterials, we found that PgP/siRhoA at N/P 30:1 showed efficient
knockdown in B35 cells, as well as rat spinal cord injury model in vivo89. These finding lead us to
choose ratios, above 30:1 (30:1, 60:1 and 80:1) for further experimentation.

Figure 5. Agarose gel shift assay of PgP complexed with siRNA. PgP binds siRNAs at various N/P ratios, with
greatest stability found at and above N/P of 15:1
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5.2 PgP/siMGMT polyplex characterization
The characteristics of the PgP/siRNA polyplex were next evaluated. The particle size,
polydispersity index and zeta potential, or polyplex surface charge, are displayed in Table 2. The
mean polyplex particle size found using the Zetasizer ZS was about 192 nm with a PDI of 0.19.
The polydispersity index is expected for a micellar complex such as PgP/siRNA due to the
PgP/siRNA

PgP/siRNA

N/P Ratio

30:1

60:1

Particle Size (nm)

201.42 ± 4.17

192.2 ± 69.23

PDI

0.238

0.191

Zeta Potential (mV)

30.63 ± 1.60

47.5 ±6.72

(A)

(B)

(C)
Figure 6. Characterization of PgP/siMGMT. (A) PgP/siMGMT polyplexes were characterized for particle
size and zeta potential using a Zetasizer NS and N/P ratios of 30:1 and 60:1. (B) The distribution of particle
size is graphed versus intensity, displaying the average particle size around 200 nm. (C)Transmission
electron microscope (TEM) image of PgP-complexed siRNAs at a 30:1 N/P ratio. Gwak, S-J et al. (2016)
Acta Biomaterialia, 35:98-108.

formulation methods. The zeta potential, a key indicator of the stability of colloidal dispersions,
is about 48 mV, showing moderate stability (Fig. 6).
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The net positive charge, from the positively charged PEI shell overcomes the siRNA’s negative
charge at this N/P of 60:1. Positively charged particles in the body have the tendency to interact
with negatively charged proteins, which lead us to test PgP in heparin competition and serum
protection assays. The polyplexes were imaged previously by Gwak et al., and displayed in in
Figure 6. They were imaged with transmission electron microscope (TEM) at 30:1 are shown to
create relatively uniformly sized and spherical polyplexes.89
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5.3 PgP delivers siRNAs into glioblastoma cells in vitro
Once the ability of PgP to bind free siRNAs was confirmed, we examined the ability of PgP to
deliver siRNAs into cells in vitro. T98G human glioblastoma cells were incubated with FI-siNT
alone, or complexed with PEI, lipofectamine 2000, or PgP for 6 hours.

Figure 7. PgP delivers siRNAs into GBM cell in vitro. PgP at N/P ratios of 30:1, 60:1, and 80:1 mediates the
uptake of green fluorescently labeled siRNA. Images taken my fluorescent microscopy 6 hours posttransfection.

Qualitatively, fluorescent microscopy revealed that the PgP/FI-siNT complex produced uptake of
the siRNA in T98G cells, shown in figure 7. Both the intensity and amount of green fluorescence
was taken into account when visually observing transfection. When delivered alone, siRNA does
not appear to enter the cell, or remain intact. Visually, the optimal uptake was at N/P ratio of
60:1, but ratio 30:1 was similar. The N/P ratio of 80:1 appears to display a lower degree of
uptake, but this is likely due to fluorescent signal quenching from the strong electrostatic
interaction. Results were comparable to strong commercially available transfection agent
Lipofectamine, and appeared to produce stronger signal than delivery with PEI.
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Figure 8. PgP mediates uptake of siRNAs in human glioblastoma. T98G cells with quantitative flow cytometry
analysis of siRNA uptake in T98G cells 6 hours post-incubation with siRNA alone, or siRNA complexed with
polyethyleneimine (PEI) at a 5:1 N/P ratio, Lipofectamine 2000 (Lipo2000), or PgP at a 30:1, 60:1, or 80:1 N/P ratios.
Data are mean ± SEM of three independent experiments (N=3) where ****P<0.0001 or not significant (ns)
compared to untreated cells (one-way ANOVA).

Flow cytometry was used to quantify the intracellular uptake of siRNA delivered by PgP
6 hours post-transfection. When quantified, no significant difference was seen between each
ratio, or the positive transfection controls of PEI and LIPO2000. Over 90% transfection efficiency
was observed in all PgP ratios, PEI and LIPO2000, confirming the efficacy of PgP as a nucleic acid
delivery system. This data supports the theory that the discrepancy between qualitative and
quantitative results is due to quenching from strong positive charge of PEI in both the PEI
positive control and the PgP 80:1. The siRNA alone showed no significant uptake compared to
the untreated control, suggesting that the cells had almost zero transfection.
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5.4 siRNA delivery displays minimal cytotoxicity in vitro

Figure 9. PgP polyplexes display minimal cytotoxicity in T98G cells. Quantitative analysis of T98G cell viability via
MTT assay following 48-hour incubation with a non-targeting siRNA (siNT) alone or siNT complexed with
Lipofectamine 2000 (Lipo2000) or PgP at a 30:1, 60:1, or 80:1 N/P ratio. Data are mean ± SEM of three independent
experiments (N=3) performed in triplicate where the data is not significant compared to untreated cells (one-way
ANOVA).

Cytotoxicity of the PgP polyplexes in T98G cells was determined by the performance of MTT
assay after transfection. Cells were treated with siNT alone or complexed with LIPO2000, or PgP
at N/P ratios of 30:1, 60:1 and 80:1. The results showed minimal cytotoxicity for all treatments
in comparison to untreated cells (Fig. 9). The percent viabilities for cells treated with PgP
polyplexes were 85%, 90%, and 93%, at N/P ratios of 30/1, 60/1, and 80/1, respectively,
compared to 88% viability for cells treated the lipofectamine 2000/siNT. Overall these results
demonstrate that PgP mediates efficient uptake of siRNAs into glioblastoma cells with minimal
cytotoxicity, showing the potential utility of PgP as a vector for siRNA delivery.
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5.5 Polyplexes enter the cell through endocytosis

Figure 10. PgP polyplexes enter the cell through endocytosis. Endosomes were labeled with Lysotracker blue fluorescent label, and
siRNA was labeled with green fluorescent FI-siNT. Colocalization of endosomes and siRNA suggested the cellular uptake of the
polyplexes was occurring at the one hour timepoint.

Images of T98G cells were taken to visualize uptake after transfection and staining. The
LysoTracker™ Blue stains the acidic organelles, indicating location of endosomes. Fluorescently
labeled FI-siNT indicated location of the siRNA uptake within the cell. Fluorescent images of
PgP/FI-siNT transfected cells showed colocalization of the endosomes and FI-siNT, indicating
that the uptake of siRNA is mediated by endocytosis via endosomes. Images of the control, cells
treated with siRNA alone, show that little green fluorescence remains after the incubation, but
also that the clearly defined endosomes do not co-localize with the FI-siNT. Positive control
LIPO2000 displays clear colocalization, comparable with that of PgP polyplexes. These results
confirm the theorized method of cellular uptake of the polyplexes.
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5.6 PgP mediates MGMT silencing

MGMT mRNA
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Figure 11. PgP polyplexes mediate silencing of MGMT in T98G cells. (A) Western blot analysis of MGMT protein
levels or (B) Real-time PCR analysis of MGMT mRNA levels in T98G cells 48 hours post-treatment with siMGMT
complexed with Lipofectamine 2000 (Lipo2000) or PgP at a 30:1, 60:1, or 80:1 N/P ratio, compared to cells treated
with Lipo2000 or PgP complexed with non-targeting siRNA (siNT) at the same N/P ratio. β-Actin protein levels were
monitored to ensure equal loading of samples. The MGMT mRNA levels were normalized to 18s endogenous mRNA
levels. Data are mean ± SEM of three independent experiments performed in triplicate, where *P<0.05, **P<0.01,
and ****P<0.0001 (t-test) compared to cells treated with siNT-complexed PgP or Lipo2000 at the same N/P ratio.

After the delivery efficiency and stability of the complex was determined, analysis of the
silencing effect of siMGMT in vitro was evaluated. The silencing of MGMT was observed on the
mRNA and protein levels. By performing a western blot, the knockdown of MGMT on the
protein level can be visualized, as shown in Figure 11A. Positive protein control B-Actin is used
to visualize that comparable protein is expressed in each sample. Comparing to non-targeting
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controls, lighter bands are seen at N/P ratios of 30:1, 60:1 and 80:1, suggesting specificity of the
gene silencing. Very significant reduction in expression is best visualized at N/P 80:1. At the
mRNA level, knockdown was quantized using RT-PCR, displayed in Figure 11B. The expression
was normalized to endogenously expressed 18s mRNA levels, and normalized to non-targeting
controls to compare true percent expression in each sample. All N/P ratios display significant
reduction in expression, and over 50% knockdown is seen at N/P 60:1 and 80:1. The N/P ratio of
60:1 was chosen to move forward with in studies, because of its significant ability to silence
MGMT, while minimizing the amount of nucleic acid used. Minimization of the total siRNA
amount is important in preventing possible toxicities in vivo.
5.7 PgP protects siRNA in physiological conditions
5.7.1 Serum protection assays
To determine the ability of the PgP to protect siRNA from degradation in relevant physiological
conditions, polyplexes were incubated with 10% or 50% serum (FBS) for 1 hour postcomplexation. In images of polyplexes after electrophoresis, PgP shows to protect the siRNA
after incubation in both 10% (Fig. 12A) and 50% serum (Fig. 12B), compared to when incubated
in water. Protection is determined by the amount of siRNA that travels through the gel to the
end compared to the negative control, siRNA alone, and positive controls PEI/siRNA and
LIPO/siRNA, which are known to complex with and protect nucleic acids. After incubation in
serum, the strong detergent SDS is used to dissociate the PgP from the siRNA, allowing
remaining siRNA to run through the gel. When siRNA alone was incubated in serum conditions,
little siRNA remains after the gel is run, compared with control siRNA incubated in water.
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A)

B)

Figure 12. Polyplexes protect siRNA from degradation in 10% and 50% serum conditions. A) siRNA alone or
complexed with PgP (N/P 60:1), PEI (N/P 5:1) and LIPO were incubated in A) 10% serum or B) 50% serum for 1 hour.
Remaining siRNA at the bottom of the gel suggests PgP protects siRNA in 10% serum (A) and 50% serum (B).

Positive controls PEI/siRNA and LIPO/siRNA display maximal siRNA protection in serum and
water, comparable to the siRNA protection seen with PgP. Streaking observed in the 10% and
more heavily in the 50% gel is likely due to serum protein interactions or binding, where greater
degree of binding is seen in the 50% serum than 10% serum conditions. Human blood conditions
are comparable to 50% serum conditions, so although some protein binding was apparent, the
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high degree of siRNA protection compared to controls confirms the ability of PgP to deliver
siRNA in vivo.
5.7.2 RNase protection assay
PgP/siRNA 60:1 was next complexed and incubated for 1 hour in water or 0.01µg RNase A, a
commercially available endoribonuclease that specifically degrades single-stranded RNA at C
and U residues. When siRNA alone was incubated in RNase, no siRNA could be seen after the gel
was run, indicating that the RNase will completely degrade ribonucleic acids. The PgP/siRNA
complex shows no detectable degradation after RNAse incubation, compared with the complex
incubated in water or positive controls PEI/siRNA and LIPO/siRNA.

Figure 13. Polyplexes protect siRNA from degradation due to ribonucleases. siRNA alone or complexed with PgP
(N/P 60:1), PEI (N/P 5:1) and LIPO were incubated in 0.01µg of RNase A. PgP shows to protect the siRNA from total
degradation, as seen when siRNA alone is incubated in RNase A.
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5.7.3 Heparin competition assay
PgP/siRNA 60:1 polyplexes were incubated with heparin at various weight ratios (WR, Heparin:
siRNA) to assess competitive dissociation. The polyanion heparin is a negatively charged
polysaccharide that can compete with nucleic acids for the interactions with polycations
present, such as the PEI shell of PgP. After incubation, gel electrophoresis was run, and samples
were compared to a control of siRNA alone, where the free siRNA ran through the gel
completely. At a weight ratio of 5:1, dissociation of the PgP/siRNA polyplex begins, as some

Figure 14. Polyplexes remain stable in the presence of heparin up to a weight ratio (WR) of 10:1. siRNA alone or
complexed with PgP (N/P 60:1) was incubated with heparin at various weight ratios, ranging from 0 to 100. The
polyplex shows stability up to the WR 5:1, where dissociation begins. Total dissociation is seen at WR of 10:1.

siRNA travels through the gel. At a WR of 10:1, the siRNA almost completely travels through the
gel, suggesting that heparin competitively interacted with the complex and bound to the PgP,
displacing siRNA. We can conclude that at some WR between 5:1 and 10:1, the polyplex does
not completely dissociate, and at some WR between 2:1 and 5:1 and below, the polyplex is
completely stable. These results demonstrate the stability of the polyplex in various
physiological conditions, allowing us to predict the stability of the polyplexes in vivo.

48

5.8 Effect of MGMT knockdown on TMZ cytotoxicity

Figure 15. Combination PgP/siMGMT and temozolomide treatment reduces viability of T98G cells. Quantitative
analysis of T98G cell viability via MTT assay 72 hours post-treatment with PgP-complexed siMGMT with or
without concurrent temozolomide (TMZ) treatment of 500 or 1000 µM. Untreated cells and cells treated with
PgP complexed with a non-targeting siRNA (siNT) were used as negative controls. Data are mean ± SEM of two
independent experiments performed in triplicate.

The IC50 (half maximal inhibitory concentration), or 50% lethal dosage for TMZ in T98G cells was
determined to be 1000µM TMZ. Once cells were treated with PgP/siMGMT or PgP/siNT, TMZ
was added at 1000µM and 500um (half the IC50) and incubated for 72 hours. After 72 hours, an
MTT assay was performed. Percent viability determined was normalized to untreated control. As
displayed in Figure 15, a reduction in viability is apparent when PgP/siMGMT is used in
combination with TMZ. After statistical analysis using one-way ANOVA, no significance was
found between the PgP/siNT with TMZ group and the PgP/siMGMT with TMZ group. Therefore,
a reduction in viability cannot yet be attributed to the silencing effect of siMGMT when treated
in combination with TMZ. A reduction in cell viability is certainly apparent, but a larger sample
size may be necessary for conclusive results.
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5.9 Xenograft glioblastoma model in mouse brain was verified
5.9.1 H&E staining
After injecting T98G cells into the mouse brains, the tumors were allowed to grow for 4 weeks.
After 4 weeks, one mouse was sacrificed and the brain was harvested and preserved in 10%
formalin for 24 hours and then 30% sucrose for 48 hours. Cryosectioning and Hematoxylin and
Eosin (H&E) staining was performed to visualize the histological structure of the brain at the
injection site. The slides prepared allowed us to see distinct tumor cells within the brain. As
common with naturally occurring glioblastomas, the cells are diffuse and spread into the normal
brain tissue, rather than forming a solid tumor mass. The cells can be identified in Figure 16,
differentiated from normal tissue due to their fibroblastic morphology. At 2.5X, the injection site

#

+

*
+
2.5
X

10X

5X

Figure 16. Glioblastoma cells visualized within mouse brain tissue ex vivo. At 2.5X magnification, the injection
site can easily be seen, indicated by #. At 5x, a lesion is noted near the injection site, above the hippocampal
region, indicated by *. At 10X, the fibroblastic glioblastoma cells can be seen spreading into the ventricle,
indicated by +.

is easily visualized, where it has not healed fully. The sample shows that the right ventricle (side
of injection) is significantly smaller than the left ventricle, suggesting that the GBM tissue has
invaded the brain and is growing into the right ventricle. At 5X, the ventricle shows to have GBM
cells within, and there is a lesion lateral and dorsal to the ventricle. At 10X, the cells can be more
easily visualized, spreading throughout the ventricle.
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5.9.2 Ex vivo imaging
After the polyplex injection and 72-hour incubation, the animals were sacrificed and brains
removed. Brains were stored in RNAlater for 24 hours, and then placed into a mouse brain
matrix for dissection. A slice was removed 1mm posterior and 1 mm anterior to the injection
site (2mm total thickness). The slices were imaged with a dissection scope at 18X. The images
showed the reduction in right ventricle size, compared to the left ventricle, for control, nontargeting and siMGMT groups, displayed in Figure 17.

Figure 17. GBM xenograft tumor model verified after sacrifice. Reduction in ventricular space indicates tumor
growth in the right hemisphere, where injection was performed. Asterik (*) indicates the approximate cellular
and/or treatment injection location in (A) control group, (B) PgP/siNT group and (C) PgP/siMGMT treatment
group.

5.10 DiR-loaded PgP/siNT remains in tumor for up to 10 days
IVIS imaging done at 1, 3, 6 and 24 hours, 48, 72 hours and then every 48 hours up to 10 days
showed that the DiR-loaded polyplex remained in the brain tissue for at least 10 days. The
minimum radiant efficiency was set to 5x106 to allow for comparison across photos. The
polyplex could be seen in the spleen with intensity after 24 hours and sporadically throughout
imaging. The signal in the brain seems to remain consistent with each sampling. At 10 days after
harvesting organs, the signal could be detected in the brain, but not in any other organs as seen
in Figure 19. This suggests that the polyplex is accumulating in the brain tissue and remains for
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up to 10 days without total clearance. The lack of signal in the rest of the organs suggests that
there is no significant accumulation in peripheral organs. Clearance in the seen is expected, due
to the nature of the positively charged polyplex, and the preference by the spleen to clear
positively charged molecules.

Figure 18. Local delivery of DiR-loaded PgP/siNT into tumor site (right mouse). Left mouse is control mouse with
tumor but without DiR- PgP/siNT injection. A) 1 hour post injection, B) 24 hours post injection, C) 48 days post
injection, D) 72 days hours post injection, E) 4 days post injection, F) 6 days post injection, G) 8 days post
injection, H) 10 days post injection. Strong DiR signal is observed at each timepoint, with little reduction in
strength over 72 hours.
Figure 19. DiR-loaded PgP/siNT remains in
the brain tissue for at least 10 days. Organs
harvested from control mouse (right) versus
DiR-PgP/siNT treated mouse (left). Organs
from top to bottom: brain, heart, lungs,
liver, kidneys, spleen. No polyplex
accumulation is observed in organs after 10
days. Signal remains strong (7.4x107 radiant
efficiency) in the brain tissue 10 days postinjection.
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5.11 PgP/siMGMT polyplex mediates MGMT knockdown in vivo
Once the polyplex biodistribution was evaluated in vivo, the therapeutic effect was studied. One
month post-xenograpft, the mice were injected with either PgP/siNT, as a non-targeting control
or PgP/siMGMT for therapy. Control mice were not injected with therapeutic, but were injected

Control

siNT

siMGMT

MGMT
β-actin
Figure 20. PgP mediates knockdown of MGMT expression in vivo. Expression of MGMT on the (A) mRNA and (B)
protein levels of brain tumor tissue harvested 72-hours post-injection of PgP/siNT or PgP/siMGMT. Values are
normalized to MGMT expression of control group. Data are mean ± SEM, where *P<0.05. β-actin as endogenously
expressed protein control.

initially with the GBM cells. Brain tissue was harvested 72 hours post-injection. The silencing of
MGMT mRNA was evaluated using RT-PCR, and results are displayed in Figure 20. The group of
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mice treated with PgP/siMGMT shows significant reduction is MGMT expression compared to
the control group, displayed in Figure 20A. There is no significant difference between the control
group and the mice treated with PgP/siNT, suggesting that the non-targeting control did not
knockdown MGMT. Western blot showed that the PgP/siMGMT had knockdown at the protein
level compared to non-targeting and untreated controls, displayed in Figure 20B. These results
are consistent with the silencing effect seen in vitro, and provide promise that PgP is an effective
method of gene delivery in vivo. The safety of the therapy can be commented on, in that no
deaths or adverse effects occurred within the 72 hours after injection.
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CHAPTER 6
DISCUSSION
The overall goal of this project was to use our lab’s novel delivery system, PgP, to effectively
deliver siRNA in vitro and in vivo, to glioblastoma cells. Proving the efficacy and safety of
siMGMT delivery would be relevant for the treatment of glioblastoma, in that it may allow for
an increase in TMZ cytotoxicity. Increasing the toxicity would first allow for better treatment of
the disease, eliminating more tumor cells from the body. It could further allow for lower
dosages and therefore reduced toxic side effects, such as life-threatening myelosuppression.
After evaluating our results, there are a few highlights and a few limitations that should be
addressed. First, the delivery system PgP has been shown to be very effective in vitro for
delivery of siRNA into T98G cells. It provides for over 90% transfection and over 50% gene
knockdown. However, in vitro conditions are very different from those of the human body,
mainly in that we see cancer cells growing in a very controlled monolayer, compared to the
unpredictable diffuse nature of gliomas in humans, where cancerous cells spread easily into
normal regions of the brain. The H&E staining of brain sections gave us insight into the
development of xenograft T98G tumors in nude mice. Although no visible tumor borders were
clear, the individual GBM cells were apparent in the injected hemisphere, traveling easily
through the ventricle. The ex vivo slicing of the brain tissue displayed clear asymmetry between
the right and left hemispheres.
After DiR-PgP/siNT injections and imaging, the polyplex appears to remain stable in the brain
tissue, and doesn’t seem to accumulate in the peripheral organs. Though, there are limitations
to the method of local delivery, in that it may not represent the accumulation of the polyplex in
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the tumor if it were to be administered intravenously. Local injection was also used for the
treatment administration, which is reasonable and potentially translatable to the clinic, but
could cause high risk of local side effects such as infection. Minimizing the number of times that
the skull is opened for surgery is preferred to reduce contact with pathogens, especially because
treating infection in the brain is challenging.
After evaluating the gene silencing at the mRNA level in vivo, we can conclude that the delivery
of siMGMT is feasible, but results had some inconsistencies. In order to determine the silencing
effect with more accuracy, future studies should be done. Creating a tumor model using
different cell lines may be more effective in creating solid tumors. Solid tumor tissue would
allow for better removal of tissue and better analysis. It is likely that normal brain tissue was
being analyzed within our tumor tissues, but in different amounts, causing variation in MGMT
expression. Western blot displayed very light bands compared to β-actin control, suggesting that
the MGMT levels are very low, even in control groups This may also give reason to the
inconsistencies seen in the data after evaluating knockdown on the mRNA level.
The combinatorial studies done, where we attempted delivering siMGMT and TMZ either
simultaneously or in sequence, did not provide conclusive results. The study may provide insight
into the efficacy of TMZ in general. Studies done found that it was extremely difficult to produce
cell death, even with high concentrations of TMZ applied directly to the cells. In comparison to
1000µM TMZ, the amount of CCNU to achieve IC50 on the T98G cells plated the same is only
50µM. A more effective chemotherapeutic is needed to effectively kill GBM cells. The study
may also be limited in the methods being used. MTT assay provide a measure of metabolic
activity of the cells after treatment. A TUNEL assay may be attempted for future studies, where
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the apoptotic activity of the cells is quantified. Because TMZ causes double stranded DNA
breaks, this could be an appropriate method to more accurately determine the efficacy of the
combination treatment. Increasing sample size further could provide for more reliable results.
Another outlook for this project would to be to effectively load an alkylating agent into the
hydrophobic core of the PgP complex for more effective delivery of chemotherapeutics into
glioblastoma cells. TMZ is nearly insoluble (5mg/ml) in water, so the hydrophobic core of PgP
could potentially be an appropriate intermediate to delivery. Future work can be done with this
to load the TMZ within the PgP and deliver the drug more effectively. Future work should
include optimizing TMZ loading in PgP, as well as attempting to load other alkylating drugs such
as lomustine (CCNU).
Further additions to the delivery system could include adding a targeting moiety and additional
siRNA conjugates. A targeting moiety can be used to actively target the tumor tissue, in addition
to the passive targeting technique. Possible treatments to be attempted in vivo could include:
sequential delivery of PgP/siMGMT and then delivery of targeted TMZ-loaded PgP. Optimization
of maximum MGMT knockdown in vivo should be determined, to administer the drug loaded
PgP when it will be most effective. Additional siRNAs could be complexed with PgP, such as to
interfere with oncogenic, tumor promoting genes, while providing an environment for TMZ to
work optimally. Certain angiogenic genes that could be considered for knockdown include
vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), or plateletderived growth factor (PDGF). EGFR and PDGF are overexpressed in primary and secondary
GBM, respectively, therefore could have positive effects if silenced in different GBM patients.
VEGF is a key angiogenic factor, allowing for vessel formation and tumor proliferation in many
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cancer types, and is already being inhibited as a treatment for GBM (bevacizumab). The codelivery of these siRNAs using the stable polymeric delivery system could further enhance
treatment of GBM.
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CHAPTER 7
CONCLUSION

In conclusion, it can be confirmed that PgP complexes with siRNAs and effectively mediates the
delivery of siMGMT into T98G cells. It does so without significant cytotoxicity at N/P ratios of
30:1, 60:1 and 80:1. The PgP/siMGMT polyplex allows for significant reduction in expression on
the mRNA and protein levels in vitro, with over 50 percent knockdown at using N/P ratios of
60:1 and 80:1. The N/P ratio of 60:1 was chosen as the ratio to move forward with in order to
limit potential toxicity in vivo, by reducing total amount of reagent used, while still achieving
over 50% gene silencing. Studies show that PgP protects siRNA from degradation in serum
conditions and in the presence of ribonucleases, giving reason the believe that it will remain
stable in the body.
In vivo results display the ability to grow T98G glioblastoma cells in nude mice, but the ability to
form a solid tumor is not certain. Silencing of MGMT was found to be effective in mice on the
mRNA and protein levels, however very little MGMT expression is apparent, causing variability
in results. While significance is seen between the MGMT knockdown and control groups, the
significance is only one star, where P< 0.05, reflecting these variabilities. The combination of
PgP/siMGMT and TMZ shows decreased cell viability at 500µM and 1000µM, however no
statistical significance was found between combination therapy of PgP/siMGMT + TMZ and
combining PgP/siNT +TMZ. This may be due to in inability of TMZ to effectively kill glioblastoma
cells, rather than the efficacy of the PgP/siMGMT polyplex.
Polymeric drug delivery shows great potential in the field of cancer treatment. Delivering drugs
and genes using a multifunctional nanotherapeutic can help overcome the physical barrier of
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the BBB, and combat chemotherapeutic resistance with gene therapy. PgP has great potential in
becoming a new dual treatment for not only GBM, but many therapeutic areas. With further
studies, we can hope to optimize the use of this carrier for the combinatorial delivery of
siMGMT and TMZ, and bring longer lives to GBM patients.
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